Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

Table 3 Univariate and multivariate analyses for relapse free survival

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95 % CI	P	HR	95 % CI	P
Age (≤median)	0.685	0.364–1.287	0.240		-
Menopausal status (Premenopausal)	0.846	0.449–1.594	0.605		-
pCR	0.342	0.082–1.420	0.140		-
AJCC response (CR plus PR)	0.309	0.172–0.556	0.000	0.374	0.192–0.728	0.004
Surgery (BCS)	0.428	0.228–0.803	0.008	0.475	0.252–0.894	0.021
Pathologic Stage (yp0,I)	0.235	0.092–0.600	0.002	0.267	0.094–0.756	0.013
Hormone receptor positive	0.447	0.236–0.846	0.013	0.402	0.198–0.818	0.012
HER2 positive	1.059	0.761–1.474	0.734		-
TNBC	1.038	0.056–2.131	0.919		-
Subtype (Luminal A)	0.379	0.145–0.985	0.047	0.314	0.103–0.962	0.043

pCR pathologic complete response, CR complete response, PR partial response, BCS breast conserving surgery, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer, HR hazard ratio, 95 % CI 95 % confidence interval, P p-value

ISSN: 1471-2407